Drug Trial Radar · NCT02160678
Generic Tazarotene Cream, 0.1% in the Treatment of Acne Vulgaris
Last checked: Nov 19, 2026Latest source record: Nov 3, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,741
Actual
Start
May 2014
Primary completion
Jul 2015
Study completion Jul 2015
Sponsor
- Lead sponsor
- G & W Laboratories Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 11, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years, up to 40 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To compare the safety and efficacy profiles of Tazarotene Cream, 0.1 % to the reference listed drug Tazorac® (tazarotene) Cream, 0.1 % in order to demonstrate bioequivalence, and to demonstrate superiority of the 2 active creams over that of the cream vehicle (placebo) in the treatment of acne vulgaris.
Conditions
- Acne Vulgaris
Interventions
VehicleDrug
Cream Vehicle (placebo) (G \& W Laboratories, Inc.)- vehicle
Tazarotene Cream, 0.1 %Drug
Tazarotene Cream, 0.1 % (G \& W Laboratories, Inc.) - test product
Tazorac Cream, 0.1%Drug
Tazorac Cream, 0.1% (Allergan, Inc.) - reference product
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluation of equivalence of the test product to the reference productTime frame: Week 12
- Evaluation of superiorityTime frame: Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Altman Dermatology Associates
Arlington Hts., Illinois
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.